A Phase 2 Multicenter Single-Arm Clinical Trial of Zanzalintinib and Pembrolizumab in Subjects With Resectable Clear Cell Renal Cell Carcinoma

Clinical trial NCT07691476 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07691476
Sponsor: Yonsei University
Status: NOT_YET_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Patients With Locally Advanced or Metastatic But Resectable Clear Cell Renal Cell Carcinoma

Start date: 2026-10-01
Primary completion: 2028-10-31
Enrollment: 48

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.